Mindspeed Gets $5.3M In Patent Sale

socalTECH

Newport Beach-based semiconductor firm Mindspeed Technologies announced today that it has sold of a portfolio of legacy patents, for $5.3M. Specific details on the sale and the buyer of the patents was not disclosed by the company. The firm said the new sale comes on top of a previously announced, $10.0M patent sale it announced in July. Mindspeed said the patent sales puts the firm in its "strongest net cash position in over five years."

Glaukos Settles Patent Suit

socalTECH

Laguna Hills-based medical device maker Glaukos said this morning that it has entered into a settlement of a patent lawsuit with Transcend Medical. According to the company, it has agreed not to sue Transcend for patent infringement related to Transcend's CyPass Micro-Stent devices. In exchange, it said Transcend will pay the company 1% of future net sales, via quarterly payments, up to a maximum amount of $6M.

Plan for your R&D Tax.

Berkonomics

Companies that are successful with their first product must begin thinking about the costs of additional products or of that product’s replacement well before any evidence of a peak in sales is noticed.

.Net 170

Wasted time is money lost.

Berkonomics

Since this number is budgeted and pre-authorized, managers tend to focus upon other things such as sales, marketing and product development issues. Not long after, the company was sold in a “fire sale” amounting to slightly less than the debt on the books. Close.

.Net 263

Wasted time is money lost. (And another story of lost opportunity.)

Berkonomics

Since this number is budgeted and pre-authorized, managers tend to focus upon other things such as sales, marketing and product development issues. There is an art to efficient management of a process, whether that is the process of bringing a product to market from R&D to production or developing a new product’s launch program. Not long after, the company was sold in a “fire sale” amounting to slightly less than the debt on the books.

.Net 181

Bio Roundup: FDA Says No, PCSK9 Value Fight, CRISPR Intrigue & More

Xconomy

And once in a while, a defender uses his or her face, inadvertently, to block a ball spiked over the net. All those years of hard work to reach the promised land, then just as a drug owner is ready to spike it home and take a victory lap, the FDA’s hands rise over the net… OK, it’s not a perfect analogy, but it’s better than comparing the patent fight over the gene editing system CRISPR-Cas9 to table tennis. (Be

Interview with Cliff Rees, XCast Labs

socalTECH

They can call us, we turn it into a IP call, and a 10 digit phone number, we then figure out where that user is on the planet, and deliver it over IP, making it a complete on-net call. The reverse also happens--if one of our users wants to call Skype users, they can do that purely on the net, without using the PSTN. We've got patents on technology that helps save bandwidth utilized for VoIP calls and particularly for video.

IP 143

Interview with Dipanshu Sharma, Kadonk

socalTECH

There was a disconnect between the product and the sales process. Angels have lost lots of net worth because of the stock market meltdown, so we've kept it small, and plan to keep it small--at most three to five people at the most by the end of the year. Anders and I own a multitude of patents at Nokia--I have 11 at Nokia--and we were inventing technology all the time.

CIO 100